| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | SCHEDULE 13G |
| 13 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Primary efficacy endpoint achieved based on preliminary results from a November 5th data evaluation |
| 13 Nov 2026 | FWP |
| 13 Nov 2026 | 424B5 |
| 10 Nov 2026 | EFFECT |
| 05 Nov 2026 | S-3 |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
REDWOOD CITY, Calif., November 5, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), ... |
| 29 Oct 2026 |
8-K: Regulation FD Disclosure
A Late - stage Ultra - rare Disease Company Treating Refractory Hypoglycemia Corporate Presentation |
| 28 Oct 2026 | SCHEDULE 13G |
| 23 Oct 2026 |
Form 4: Evans Daron, CFO
Gave 16,000 shares as a gift · Acquired 8,000 shares (Gift) |
| 21 Oct 2026 |
Proxy statement: annual meeting on December 2, 2026
CEO pay $5.7M, up 100% · say-on-pay vote |
| 15 Oct 2026 | DRS |
| 14 Oct 2026 |
8-K: Regulation FD Disclosure
REDWOOD CITY, Calif., October 14, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced... |
| 07 Oct 2026 | PRE 14A |
| 05 Oct 2026 |
8-K: Regulation FD Disclosure
The Agency reiterated its commitment to addressing the unmet need for treatment |
| 24 Sep 2026 | 10-K |
| 24 Sep 2026 |
8-K: Results of Operations and Financial Condition
REDWOOD CITY, Calif., September 24, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), ... |
Loading...